Thursday 20 August 2026

One To Watch

Jacobio Pharma

A clinical-stage oncology company focusing on undruggable targets.

Company Overview

Want to Update your Company's Profile?


Latest Jacobio Pharma News

Jacobio Bio inks licensing deal with AstraZeneca
23 December 2025
Jacobio out-licenses glecirasib and JAB-3312 in China
2 September 2024
Positive Phase II data for glecirasib, a novel lung cancer med
2 May 2024
AbbVie exits Jacobio deal on SHP2 inhibitors
6 July 2023
More Jacobio Pharma news >


Today's issue

Opdivo intravenous infusion wins additional approval in Taiwan
Biotechnology
Opdivo intravenous infusion wins additional approval in Taiwan
19 August 2026
Pharmaceutical
FDA accepts Teva's NDA for ecopipam, grants priority review for pediatric Tourette syndrome
19 August 2026
Biotechnology
Kynexis raises 97 million euros to advance med for cognitive disorders
19 August 2026
Biotechnology
Merck and Moderna announce Phase III INTerpath-001 trial of intismeran combo
19 August 2026
Pharmaceutical
Latin America assesses and analyzes how to overcome immunization barriers in the region
19 August 2026
Pharmaceutical
Lundbeck reports financials with strong growth from Vyepti
19 August 2026
Biotechnology
Piramal completes buy of controlling stake in Yapan Bio, expanding biologics CDMO capabilities
19 August 2026




Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze